Publicaciones en las que colabora con Purificación Cid Silva (6)
2023
-
Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort
European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226
2022
-
Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study
European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211
2019
-
Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines
Journal of the International Association of Providers of AIDS Care, Vol. 18
-
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490
2018
-
Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors
AIDS, Vol. 32, Núm. 1, pp. 121-125
2017
-
Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance
Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 5, pp. 442-446